Jan 09, 2023 / 07:15PM GMT
Anupam Rama - JPMorgan Chase & Co, Research Division - VP and Analyst
All right. Let's go ahead and get started. Thanks, everyone, for coming. This is the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my colleagues, Malcolm Kuno and Priyanka Grover from the team. Our next presenting company is Neurocrine, and presenting on behalf of the company, we have CEO, Kevin Gorman. Kevin?
Kevin C. Gorman - Neurocrine Biosciences, Inc. - CEO & Director
Thank you, Anupam, and thank you, everyone, for being here today. I almost feel like I need to be running back and forth on here. Before I get started, I put up our safe harbor statement. I will be making forward-looking statements. What I want to accomplish this morning is to tell you about Neurocrine, how we -- what we look like today, what our philosophy is, what our strategy has been, that's got us here and where we see that strategy taking us throughout the rest of this decade.
And so if you look at what
Neurocrine Biosciences Inc at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot